Navigation Links
Rapidlink Critical Care Information Management System

ProductsRapidlink Critical Care Information Management System
Company Siemens Medical Solutions Diagnostics
Item Rapidlink Critical Care Information Management System
Features 
  • Complete storage and retrieval of patient results
  • Data security
  • Connectivity with HIS for demographics and billing
  • Tracking and displaying quality control samples
  • Rapidlink is user-friendly daily reports are viewed with the click of a mouse, and QC summaries are displayed on just one screen
  • Extreme reliability and stability, including a buffer that safeguards all data in the event of an interface failure
  • Rapidlink automatically matches tests with orders, so results are passed along to the LIS without operator intervention
Description Today, the importance of electronic connectivity for blood gas testing is well understood. Transmission of patient results is critical for patient care, records, and billing. A sound quality assurance program that includes connectivity is essential to ensure analyzers are operating properly.
Info Siemens Medical Solutions Diagnostics
Customer Service: 800-255-3232 or 914-631-8000
Web site: http://www.siemens.com/diagnostics-products

Related medicine products :

1. Statscan Critical Imaging System
2. Stat Profile Critical Care Xpress
3. S/5 Compact Critical Care Monitor
4. S/5 Critical Care Monitor
5. Critical Care °CureWrap
6. Essentris Critical Care
7. VERICIS Cardiovascular Information System
8. Point Of Care Testing (POCT) Information System
9. LabPak II Laboratory Information System
10. LabPak POL Plus Laboratory Information System
11. LabPak POL-S Laboratory Information System
1.0 mm Micro System. The Titanium Micro System is also useful in the practice of ENT, Neurosurgery and Handsurgery.
Grafton DBM Matrix PLF is the first bone graft material designed specifically for posterolateral fusion procedures. Unique trough-like design allows for easy use with allograft/autograft bone. Demine
Demineralized bone matrix dispensed in a syringe. DBM will be free of foreign matter. Demineralized bone matrix particle size 125 to 850 . Glycerol 70-88% by weight. Calcium content less than 8%.
...a centralized O.R. control system that empowers bo... control, better information and greater efficienc...cence, as future enhancements will mainly require ...ntirely new system. Endoalpha is unique in providi...
Medicine Products:
(Date:5/16/2008)..., May 16 /PRNewswire/ -- Law Offices of Howard G. ...o be a lead plaintiff in the,securities class acti...hased or otherwise acquired the common stock of In...cal" or the "Company") (Amex: IMA ) in the,Compan... 14, 2007 (the,"Class Period"). The shareholder la...
(Date:5/16/2008)...eport side effects, but critics want agency to act...lthDay News) -- Direct-to-consumer drug ads on tel...at would allow consumers to report adverse side ef...The experts serve on a panel that advises the U.S....are already mandated by the FDA for print ads. At ...
(Date:5/16/2008)...rs More than 500 Workers, WASHINGTON, May 16 /PRN...d emergency medical technicians in the Greater Por...ratified their first-ever contract as,Teamsters., ... now covered by a,strong contract that gives them ...id Teamsters General President Jim Hoffa., The wo...
(Date:5/16/2008)...ic disease sufferers gain benefit from calcitriol,...Day News) -- Taking activated vitamin D may cut th... chronic kidney disease by about one quarter, a ne... more than 1,400 patients, those being treated wit... had their overall risk of death lowered by 26 per...
Breaking Medicine News(10 mins):Health News:Law Offices of Howard G. Smith Announces 24 Days Remaining to Move to Be a Lead Plaintiff in the Shareholder Lawsuit Against Inverness Medical Innovations, Inc. 2Health News:FDA Panel Considers Toll-Free Number for TV Drug Ads 2Health News:FDA Panel Considers Toll-Free Number for TV Drug Ads 3Health News:Vitamin D Use Linked to Lower Mortality in Kidney Patients 2
...study that has delved into the mental psyche of hu... scars that take very long to heal. // A team of ...sociology graduate student David Russell, analyzed...ho had survived the1992’ Hurricane Andrew. These y...
... mark Sun Awareness Week found that the high death...t the most dangerous form of skin cancer. // Acco...deaths in Britain from melanoma skin cancer have r...an 1,000 a year. It showed that fewer men than wom...
...laints against 21 doctors alleged to have been inv...irector of family welfare, acting on a direction f...ts against the doctors with the Ashok Nagar police...unday. "We have filed FIRs (first information rep...
... Health & Science University Cancer Institute rese... of the often devastating// head and neck squamous...-Jing Wang, M.D., Ph.D., and his colleagues. The r...ve been published in the May 15 issue of Genes & D...
Other Medicine News:Health News:High Death Rate In UK Due To Melanoma Skin Cancer 2Health News:Mouse Model Beneficial to Study of Head and Neck Cancer 2
(Date:5/15/2008)...ostate, Colorectal and Ovarian ...Event on Sun., June 1 with Oncology Experts -, SO...tCall/ -- Poniard,Pharmaceuticals, Inc. (Nasdaq: ...ology, today announced that the Company will prese...in various tumor types and combinations, at,poster...
(Date:5/15/2008)...lects depth and breadth of, collaboration with in...r diverse forms of cancer ...), the leading IV, bisphosphonate, on relapse rate...ur oral sessions to feature RAD001, first oral onc...irst results of RECORD-1 study in renal cell ...
(Date:5/15/2008)...rstCall/ -- Sanofi-aventis,(EURONEXT: SAN and NYSE...mark ATHENA study showed Multaq(R) (dronedarone), ...with atrial fibrillation or atrial flutter,decrea... death from any,cause by a statistically significa...ndpoint. The ATHENA results will be presented at t...
(Date:5/15/2008)...re/ -- Ergonex Pharma today,announced that the Uni...granted orphan drug designation to Terguride for t...AH). Terguride is currently being evaluated for PA...A,s grant of orphan drug designation to Terguride ... program by offering regulatory,clinical developm...
Breaking Medicine Technology:Poniard to Present Clinical Data From Picoplatin Trials in Multiple Tumor Types at American Society of Clinical Oncology 2008 Annual Meeting 2Poniard to Present Clinical Data From Picoplatin Trials in Multiple Tumor Types at American Society of Clinical Oncology 2008 Annual Meeting 3Poniard to Present Clinical Data From Picoplatin Trials in Multiple Tumor Types at American Society of Clinical Oncology 2008 Annual Meeting 4Poniard to Present Clinical Data From Picoplatin Trials in Multiple Tumor Types at American Society of Clinical Oncology 2008 Annual Meeting 5Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting 2Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting 3Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting 4Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting 5Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting 6Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting 7Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting 8Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting 9Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting 10Landmark ATHENA Study Findings With Multaq(R) (dronedarone) Shows 24% Reduction In Cardiovascular Hospitalization or Death in Patients With Atrial Fibrillation 2Landmark ATHENA Study Findings With Multaq(R) (dronedarone) Shows 24% Reduction In Cardiovascular Hospitalization or Death in Patients With Atrial Fibrillation 3Landmark ATHENA Study Findings With Multaq(R) (dronedarone) Shows 24% Reduction In Cardiovascular Hospitalization or Death in Patients With Atrial Fibrillation 4Landmark ATHENA Study Findings With Multaq(R) (dronedarone) Shows 24% Reduction In Cardiovascular Hospitalization or Death in Patients With Atrial Fibrillation 5Landmark ATHENA Study Findings With Multaq(R) (dronedarone) Shows 24% Reduction In Cardiovascular Hospitalization or Death in Patients With Atrial Fibrillation 6Landmark ATHENA Study Findings With Multaq(R) (dronedarone) Shows 24% Reduction In Cardiovascular Hospitalization or Death in Patients With Atrial Fibrillation 7Terguride Receives FDA Orphan Drug Designation for the Treatment of Pulmonary Arterial Hypertension 2CV Therapeutics Reports 2007 Fourth Quarter and Full Year Financial Results 3534 1CV Therapeutics Reports 2007 Fourth Quarter and Full Year Financial Results 3534 2CV Therapeutics Reports 2007 Fourth Quarter and Full Year Financial Results 3534 3CV Therapeutics Reports 2007 Fourth Quarter and Full Year Financial Results 3534 4CV Therapeutics Reports 2007 Fourth Quarter and Full Year Financial Results 3534 5CV Therapeutics Reports 2007 Fourth Quarter and Full Year Financial Results 3534 6CV Therapeutics Reports 2007 Fourth Quarter and Full Year Financial Results 3534 7CV Therapeutics Reports 2007 Fourth Quarter and Full Year Financial Results 3534 8Tips for Troublesome Medications From the Harvard Heart Letter 12794 1Tips for Troublesome Medications From the Harvard Heart Letter 12794 2ISS Recommends Pharmion Shareholders Vote for Merger With Celgene 3533 1ISS Recommends Pharmion Shareholders Vote for Merger With Celgene 3533 2ISS Recommends Pharmion Shareholders Vote for Merger With Celgene 3533 3CMC Moffitt Partner to Study Cancer 1435 1CMC Moffitt Partner to Study Cancer 1435 2
...-Having a build-up of calcium,plaque in the arteri... from heart disease in multiple ethnic groups, acc... of Atherosclerosis (MESA),funded by the National ...nstitutes of Health. Previous studies have shown t... greater risk of,heart disease events and deaths i...
...ar 26, 2007 - Two-year results from,the Medtronic ...,clinical profile of the Endeavor(R) drug-eluting ...r of Endeavor patients who have at,least two years...deavor patients, there have been no reported cases...re-specified clinical trial,protocol definitions f...
Other Medicine Technology:Calcium Plaque Build-up in the Arteries Leads to Coronary Heart,Disease in Multi-Ethnic Groups 2Two-Year Results from the Medtronic ENDEAVOR III Trial Confirm,Stent's Positive Clinical Profile 2Two-Year Results from the Medtronic ENDEAVOR III Trial Confirm,Stent's Positive Clinical Profile 3